Suxia Luo

机构：Zhengzhou University, Henan Cancer Hospital · ORCID：0000-0002-5267-8417

发表论文 42 篇 · 总被引 599 次 · h-index 8

代表论文

• Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer (2023 · JAMA · 被引 385)
• Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study (2024 · International Journal of Surgery · 被引 36)
• Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial (2025 · Journal of Hematology & Oncology · 被引 27)
• A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. (2023 · Journal of Clinical Oncology · 被引 22)
• Abstract CT078: First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial (2023 · Cancer Research · 被引 15)
• A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 13)